Are you a male experiencing symptoms of low testosterone such as weight gain and a high-pitched voice? If so, you may want to look into a product by the name of AndroGel. This testosterone gel has ...

(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing ...

AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, ...

AbbVie must pay $150 million to an Oregon man who accused the pharmaceutical company of misrepresenting the safety risks of its AndroGel drug to treat low testosterone, a federal jury decided Monday ...

In a split decision, a federal jury in Chicago ordered AbbVie to pay $150 million in punitive damages for fraudulently misrepresenting the risks of its AndroGel testosterone replacement drug. But at ...

(Reuters) - A federal jury in Chicago on Friday found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company's testosterone ...

FILE PHOTO: A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid/File Photo By Nate Raymond (Reuters) - ...

A Collierville man has been awarded more than $140 million in a lawsuit against the makers of a testosterone drug that he says caused him to have a heart attack. A federal court jury in Chicago handed ...

Testosterone replacement with 1% testosterone gel (AndroGel 1%) is rarely associated with the development of priapism, according to a study. Arthur L. Burnett, MD, of Johns Hopkins University in ...

Antares Pharma finally has its FDA approval for testosterone replacement therapy Xyosted—and now it's revving up to take on AbbVie's market-leading AndroGel at a 20% list-price discount. With the FDA ...

FILE PHOTO: A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid By Nate Raymond (Reuters) - A U.S.

July 5 (Reuters) - A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone ...